Status:
COMPLETED
Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin
Lead Sponsor:
Hamilton Health Sciences Corporation
Conditions:
Aspirin
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Some aspirin-treated patients have a blunted pharmacological response predisposing to clinical failure. The investigators hypothesize that the blunted response often results from increased rate of pla...
Detailed Description
The specific objective of this study is to validate the Cayman Chemical serum thromboxane immunoassay as a measure of platelet production in healthy subjects who are treated with aspirin by demonstrat...
Eligibility Criteria
Inclusion
- Healthy non-smoking volunteers;
- Age ≥ 18 years;
Exclusion
- Allergy or intolerance to aspirin;
- Current pregnancy;
- Use of aspirin or drugs interfering with platelet function (NSAIDs, anticoagulants) within one week of study enrolment.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 3 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03424408
Start Date
March 1 2018
End Date
September 3 2019
Last Update
September 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thrombosis and Atherosclerosis Research Institute. Hamilton General Site
Hamilton, Ontario, Canada, L8L 2X2